These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 12774796)
21. The potential place of tenofovir in antiretroviral treatment regimens. Gazzard BG Int J Clin Pract; 2001 Dec; 55(10):704-9. PubMed ID: 11777298 [TBL] [Abstract][Full Text] [Related]
22. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients. Chetchotisakd P Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222 [TBL] [Abstract][Full Text] [Related]
23. Tenofovir: FDA hearing on important new antiretroviral. James JS AIDS Treat News; 2001 Oct; (372):2-4. PubMed ID: 11702411 [No Abstract] [Full Text] [Related]
24. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. Dore GJ; Cooper DA; Pozniak AL; DeJesus E; Zhong L; Miller MD; Lu B; Cheng AK; ; J Infect Dis; 2004 Apr; 189(7):1185-92. PubMed ID: 15031786 [TBL] [Abstract][Full Text] [Related]
25. New uses for tenofovir: more questions about d4T. Proj Inf Perspect; 2003 Jan; (35):15-6. PubMed ID: 12647676 [TBL] [Abstract][Full Text] [Related]
26. Tenofovir DF trial announced by Gilead. Eagan L Posit Living; 2000 Jul; 9(6):22, 54. PubMed ID: 12492018 [No Abstract] [Full Text] [Related]
27. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. Miller MD; Margot N; Lu B; Zhong L; Chen SS; Cheng A; Wulfsohn M J Infect Dis; 2004 Mar; 189(5):837-46. PubMed ID: 14976601 [TBL] [Abstract][Full Text] [Related]
28. Tenofovir: what have over 1 million years of patient experience taught us? Pozniak A Int J Clin Pract; 2008 Aug; 62(8):1285-93. PubMed ID: 18705824 [TBL] [Abstract][Full Text] [Related]
36. K65R, TAMs and tenofovir. Miller MD AIDS Rev; 2004; 6(1):22-33. PubMed ID: 15168738 [TBL] [Abstract][Full Text] [Related]
37. Tenofovir-associated kidney diseases and interactions between tenofovir and other antiretrovirals. Lanzafame M; Lattuada E; Rapagna F; Gottardi M; Vento S Clin Infect Dis; 2006 Jun; 42(11):1656-7; author reply 1658. PubMed ID: 16652329 [No Abstract] [Full Text] [Related]
38. The role of drug interactions and monitoring in the prevention of tenofovir-associated kidney disease. Winston JA; Shepp DH Clin Infect Dis; 2006 Jun; 42(11):1657-8; author reply 1658. PubMed ID: 16652330 [No Abstract] [Full Text] [Related]
39. [Nucleotide analog shows effectiveness in previously treated patients. The new kind of HAART]. MMW Fortschr Med; 2002 Apr; 144 Suppl 1():62-4. PubMed ID: 12043078 [No Abstract] [Full Text] [Related]
40. Experience with tenofovir disoproxil fumarate for antiretroviral therapy. Stephan C Expert Opin Pharmacother; 2008 May; 9(7):1197-209. PubMed ID: 18422476 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]